Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to determine the effect of chronic nighttime low oxygen saturations on selected body systems (liver) that break down drugs in children with obstructive sleep apnea syndrome (OSAS).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Virginia Commonwealth University
• Collaborator: University of Louisville
• Treatments: Caffeine; Dextromethorphan

Criteria

Inclusion Criteria:

• Children ages 4 to 16 years with suspected uncomplicated OSAS

Exclusion Criteria:

• Children with complicated OSAS (craniofacial abnormalities, neuromuscular disorders)

• Children who are receiving medications known to induce or inhibit hepatic CYP1A2, NAT-2, XO, CYP2D6 or CYP3A4 activity

• Children who are exposed to second hand smoke for greater than 8 hours per day.

• Children with hypersensitivity to caffeine or dextromethorphan

• Children who are receiving corticosteroids or thyroid hormone